Treatment of Subacute Cutaneous Lupus Erythematosus with Localized Skin Lesions
When subacute cutaneous lupus erythematosus presents with localized cutaneous lesions, a structured first-line treatment approach guides both topical and, where needed, systemic management.
Clinical Scenario
This protocol applies to patients with localized cutaneous lupus erythematosus skin lesions. Topical corticosteroids represent the mainstay of treatment for localized disease and are effective across subtypes of cutaneous lupus erythematosus.
First-Line Systemic Treatment — Partial Overview
When systemic therapy is warranted, antimalarial agents constitute the established first-line class of treatment in this setting. Specific agent selection and all clinical parameters are defined in the full protocol.
Dosing, safety monitoring, and the complete decision algorithm are not shown here. Access the full structured regimen below.
References
- Topical corticosteroids are the mainstay in the treatment of localized CLE being effective in all subtypes (Figure 1), but only few controlled studies have been published proving their efficacy.
- Since a long time, antimalarials are considered the first-line systemic treatment in all subtypes of CLE; however, only two randomized, double-blind studies in CLE or SLE with skin lesions were — to our knowledge — performed until now.
- We recommend to apply HCQ in a maximum daily dosage of 5 mg/kg real body weight or CQ in a maximum daily dosage of 2.3 mg/kg real body weight.
- A combination of HCQ with CQ must be avoided due to the risk of irreversible retinopathy.
View source ↗